Crown Bioscience: First Clinical Candidate Developed Using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer
Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428006002/en/
The study was the result of work by an international consortium, SuppresSTEM which included Crown Bioscience (previously OcellO B.V.) and HUB. Crown Bioscience and HUB led the design of the experiments which were executed using the high content screening platform from Crown Bioscience using HUB Organoids. These studies enabled the discrimination of antibodies that were active against a broad range of mutational profiles and tumor subtypes, with hit validation and mechanism of action studies that enabled selection of optimally performing antibodies. Follow up in vivo studies in matched patient-derived xenograft (PDX) models were also performed by Crown Bioscience.
The work, spanning about five years, involved Crown Bioscience screening a library of hundreds of bispecific antibodies and rescreening of ‘hits’ in a panel of patient-derived colorectal cancer organoids and matching normal organoids, that were developed by HUB and characterized by HUB and other consortium members. Organoids are stem cell-derived mini-organs developed from any patient resection or biopsy tissue that can be grown in the laboratory, which can be applied like conventional cell lines in early drug discovery.
“This is the first study that has used organoids exclusively for cell-based compound screening and characterization, leading to a compound entering clinical trials. This is a truly remarkable achievement that demonstrates the validity and application of HUB Organoids in high throughput screening and oncology drug discovery”, said Leo Price PhD, Senior Vice President In Vitro Oncology at Crown Bioscience.
“This groundbreaking work demonstrates the power and potential of HUB Organoid Technology”, commented Rob Vries PhD, CEO at HUB. “Using organoids, we were able to accelerate the timeline from initial discovery to clinical trials to about five years.”
Nature Cancer is a journal which covers the latest, most significant cancer-related advances across the life, physical, applied and social sciences, focusing on new approaches for the development and delivery of diagnostics and therapeutics, as well as clinical studies regarding cancer diagnosis, treatment and prevention.
Read the full paper here: https://go.nature.com/3LhuAAy
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. The company is the only preclinical CRO to hold a commercial license to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the US, Europe and Asia. Find out more: https://www.crownbio.com.
About HUB
HUB Organoids (HUB) is the global leader in the field of adult stem cell-derived organoid. The technology invented by HUB’s scientists in the lab of world-renowned Prof. Hans Clevers represents a paradigm shift for drug discovery and development, preclinical patient stratification, predictive diagnostics, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics. HUB offers licenses to its proprietary technology and provides drug screening services and access to its living organoid biobanks.
About SupresStem
The SuppresSTEM consortium was funded by EU FP7 and involved collaborative work by companies including OcellO B.V./Crown Bioscience, HUB Organoids, and Merus N.V., and international research institutions including the Hubrecht Institute, IRB Barcelona and the Sanger Institute. The Vall d'Hebron Institute of Oncology (VHIO), the Catalan Institute of Oncology and the company Xenopad also collaborated in data for this publication. The consortium set out to develop novel antibody-based therapeutics targeting cancer stem cells for the treatment of colorectal cancer as well as patient-derived organoid-based screening tools to aid drug discovery.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428006002/en/
Contact information
Media Enquiries
Crown Bioscience
Louise Stenson
pr@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SkySparc Acquires Inovotek Solutions to Strengthen Its Capital Markets Expertise and Expand Delivery Across Murex, Calypso, and FIS Platforms15.10.2025 10:00:00 EEST | Press release
SkySparc, a trusted global provider of digital transformation solutions for treasury and finance institutions, today announced the acquisition of Inovotek Solutions (“Inovotek” or the “Company”), a specialist provider of transformation services to capital markets and financial institutions. Financial terms were not disclosed. The acquisition will bolster SkySparc's position as a premier provider of comprehensive digital transformation services to capital markets clients globally. It will address critical client challenges, including regulatory compliance and complex re-platforming initiatives. Additionally, SkySparc will expand its expertise across leading trading and risk management platforms such as Murex, Calypso, and FIS. By combining Inovotek’s program management expertise with SkySparc’s established managed services and proprietary software – OmniFi and Optimizer – the Company will deliver a robust and complete offering capable of addressing the most complex and demanding client
Usercentrics Surpasses €100M ARR ($117M USD) as Market Leader in Data Privacy, Paving the Way for Privacy-Led Marketing15.10.2025 09:00:00 EEST | Press release
Usercentrics today announced it surpassed €100 million in Annual Recurring Revenue (ARR), approximately $117 million USD in late August, to the tune of profitable 45% YoY growth,powered by millions of users. This milestone elevates Usercentrics into the elite “centaur” category - SaaS companies generating over €100 million in recurring revenue annually. With fewer than 200 private companies worldwide at this level, centaur status is increasingly viewed as a more meaningful benchmark than unicorn valuations, which can be inflated by high multiples on lower revenues. The milestone cements Usercentrics’ position as the leader of a new marketing era: Privacy-Led Marketing - trusted by millions of users worldwide and strengthened through strategic partnerships with global technology leaders, including Google, Amazon, and Microsoft. Privacy Pays Off With AI accelerating and expectations rising, the connection between privacy and trust has never been more vital and the global landscape is shi
IFF to Release Third Quarter 2025 Results on Nov. 4, 202514.10.2025 23:15:00 EEST | Press release
IFF (NYSE:IFF) today announced that it will release its third quarter 2025 earnings results following the market close on Tuesday, Nov. 4, 2025. The management team will host a live webcast on Wednesday, Nov. 5, 2025, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20251014533502/en/
TRU Simulation and US Aviation Academy sign purchase agreement for five Cessna Skyhawk Veris Virtual Reality Simulators, signifying first fleet order and fixed-wing market debut14.10.2025 21:39:00 EEST | Press release
During the National Business Aviation Association – Business Aviation Convention & Exhibition (NBAA-BACE), TRU Simulation + Training Inc., a Textron Inc.(NYSE:TXT) company, and an affiliate of Textron Aviation Inc., announced an agreement with the US Aviation Academy for its purchase of five of TRU Simulation’s Cessna Skyhawk Veris Virtual Reality (VR) Simulators. This landmark agreement introduces the Veris to the fixed-wing training market and is TRU Simulation’s first fleet order for VR training devices. The US Aviation Academy has the option for a future purchase of ten additional units as part of the agreement, underscoring a shared commitment to advancing pilot training through cutting-edge VR simulation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013144401/en/ TRU Simulation and US Aviation Academy sign purchase agreement for five Cessna Skyhawk Veris Virtual Reality Simulators, signifying first fleet order and
Introducing Lasso: A New Food Tech Company Redefining Consumer Packaged Foods14.10.2025 20:34:00 EEST | Press release
Lasso today announced its official launch and the introduction of its proprietary technology, Lasso SpinTech. This breakthrough system upends the outdated standards of ultra-processed foods using physics to weave together protein and fiber to make previously unattainable new consumer products. With a new $6.5M raise, Lasso is bringing its technology to the world by launching its own brands and licensing to global partners to create a new generation of healthier foods. Guided by CEO Mike Messersmith, the Lasso team spent the past year deploying its commercial-scale technology to create innovative clean-label products including protein-packed snacks and pet food—expanding beyond its first plant-based meat application under the Tender Food brand. Lasso’s latest $6.5M in capital, led by Rhapsody Venture Partners with participation from Safar Partners, Claridge Venture Partners, and others, will enable the company to commercialize its transformative technology across new high growth food ca
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom